An Ascending Multiple Dose Study of VTP-38543 in Adult Participants With Mild to Moderate Atopic Dermatitis

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED ASCENDING MULTIPLE DOSE AND CLINICAL PROOF¿OF-CONCEPT STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF VTP-38543 IN ADULT PATIENTS WITH MILD TO MODERATE ATOPIC DERMATITIS

Intervention/treatment:
VTP-38543
Medical condition:
ATOPIC DERMATITIS
Protocol code:
VTP-38543-001
Control number:
189478
Status:
Closed
Approved:
December 10, 2015
Date Completed:
Trial phase:
Phase 1, Phase 2
For more information:
ClinicalTrials.gov - NCT02655679
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 65 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Therapeutic Area, Head
Organization
Allergan
Phone:
714-246-4500
Sponsor
VITAE PHARMACEUTICAL INCORPORATED

Locations

Alberta

Kirk Barber Research
Calgary, Alberta, T2G1B1CA
Stratica Medical Inc
Edmonton, Alberta, T5K 1X3

Ontario

Lynderm Research Inc
Markham, Ontario, L3P 1X2
The Center for Dermatology / Institution
Richmond Hill, Ontario, L4B 1A5
Windsor Clinical Research Inc
Windsor, Ontario, N8W 5L7

Quebec

Dr Isabelle Delorme Inc
Drummondville, Quebec, J2B 5L4
Innovaderm Research
Montreal, Quebec, H2K4L5

Results

See the results from the trial NCT02655679. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?